Isostructural metabolites of two anti-Parkinson drugs

被引：2
|
作者：
Simon, K
Harmat, V
Torok, Z
Bocskei, Z
Hermecz, I
机构：
[1] Chinoin Chem & Pharmaceut Works Ltd, Dept Preclin Dev, H-1325 Budapest, Hungary
[2] Eotvos Lorand Univ, Dept Theoret Chem, H-1518 Budapest, Hungary
来源：
ACTA CRYSTALLOGRAPHICA SECTION C-STRUCTURAL CHEMISTRY | 1998年 / 54卷
关键词：
D O I：
10.1107/S0108270197019896
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
The absolute configurations of desmethylselegiline hydrochloride [(R)-(-)-1-benzyl-N-(2-propynyl)ethylammonium chloride, C12H16N+.Cl-], (1), and p-fluorodesmethylselegiline hydrochloride [(R)-(-)-1-(4-fluorobenzyl)-N-(2-propynyl)ethylammonium chloride, C12H15FN+.Cl-], (2), have been determined. The two compounds are metabolites of the anti-Parkinson agent selegiline and its backup, p-fluoroselegiline. The two crystal structures are highly isostructural.
引用
收藏
页码：811 / 813
页数：3
相关论文
共 50 条
  • [41] COMPARATIVE STUDY OF EFFECTS OF ANTI-PARKINSON DRUGS ON OXOTREMORINE-INDUCED EEG AND MUSCULAR ACTIVITIES
    BAN, T
    HOJO, M
    PSYCHOPHARMACOLOGIA, 1971, 19 (01): : 1 - +
  • [42] Comparison of the effectiveness, safety, and costs of anti-Parkinson drugs: A multiple-center retrospective study
    Li, Wenting
    Zhang, Hua
    Zhang, Yuan
    Wang, Ke
    Hui, Jiaojiao
    Yi, Zhanmiao
    CNS NEUROSCIENCE & THERAPEUTICS, 2024, 30 (04)
  • [43] A multiparametric analysis of the synergistic impact of anti-Parkinson's drugs on the fibrillation of human serum albumin
    Chandel, Tajalli Ilm
    Zaidi, Nida
    Zaman, Masihuz
    Jahan, Ishrat
    Masroor, Aiman
    Siddique, Ibrar Ahmad
    Nayeem, Shahid M.
    Ali, Maroof
    Uversky, Vladimir N.
    Khan, Rizwan Hasan
    BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2019, 1867 (03): : 275 - 285
  • [44] In-vivo evaluation of prolonged release bilayer tablets of anti-Parkinson drugs in Gottingen minipigs
    Sousa e Silva, Jose Paulo
    Lobo, Jose S.
    Bonifacio, Maria J.
    Machado, Rita
    Falcao, Amilcar
    Soares-da-Silva, Patrcio
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2011, 63 (06) : 780 - 785
  • [45] ANTIMUSCARINIC ACTIVITY OF ANTI-PARKINSON DRUGS ON PERIPHERAL STRUCTURES AND CORRELATION WITH CENTRAL EFFICACY OR CLINICAL DOSAGE
    OELSZNER, W
    WALTHER, H
    WAGNER, U
    ACTA BIOLOGICA ET MEDICA GERMANICA, 1971, 26 (05) : 1045 - +
  • [46] Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline
    Youdim, MBH
    Weinstock, M
    MECHANISMS OF AGEING AND DEVELOPMENT, 2002, 123 (08) : 1081 - 1086
  • [47] EVALUATION OF CILADOPA HYDROCHLORIDE AS A POTENTIAL ANTI-PARKINSON DRUG
    KOLLER, WC
    FIELDS, JZ
    GORDON, JH
    PERLOW, MJ
    NEUROPHARMACOLOGY, 1986, 25 (09) : 973 - 979
  • [48] Quantum chemical analysis of potential anti-Parkinson agents
    Razzaghi-Asla, Nima
    Shahabipour, Sara
    Ebadi, Ahmad
    Bagheri, Azam
    JOURNAL OF CHEMICAL SCIENCES, 2015, 127 (07) : 1211 - 1220
  • [49] Quantum chemical analysis of potential anti-Parkinson agents
    NIMA RAZZAGHI-ASL
    SARA SHAHABIPOUR
    AHMAD EBADI
    AZAM BAGHERI
    Journal of Chemical Sciences, 2015, 127 : 1211 - 1220
  • [50] The discovery and development of rasagiline as a new anti-Parkinson medication
    Finberg, John P. M.
    JOURNAL OF NEURAL TRANSMISSION, 2020, 127 (02) : 125 - 130
12345